Docoh
Loading...

PCSA Processa Pharmaceuticals

Document_and_Entity_Informatio

Document and Entity Information3 Months Ended
Jun. 30, 2014
Document and Entity Information'
Entity Registrant Name'Heatwurx, Inc.
Document Type'10-Q
Document Period End Date30-Jun-14
Amendment Flag'false
Entity Central Index Key'0001533743
Current Fiscal Year End Date'--12-31
Entity Common Stock, Shares Outstanding8,430,665
Entity Filer Category'Smaller Reporting Company
Entity Current Reporting Status'Yes
Entity Voluntary Filers'No
Entity Well-known Seasoned Issuer'No
Document Fiscal Year Focus'2014
Document Fiscal Period Focus'Q2

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)Jun. 30, 2014Dec. 31, 2013
Current assets:''
Cash and cash equivalents$39,899 $186,864
Accounts receivable99,03019,200
Prepaid expenses and other current assets120,82280,386
Inventory206,277228,256
Total current assets466,028514,706
Other assets:''
Equipment, net of depreciation443,668369,775
Intangible assets, net of amortization1,875,0022,053,572
Total other assets2,318,6702,423,347
Total assets2,784,6982,938,053
Current liabilities:''
Accounts payable111,96277,028
Accrued liabilities155,474258,006
Advance payment'155,497
Loan payable, current44,29041,186
Current portion of notes payable250,000590,000
Total current liabilities561,7261,121,717
Long-term liabilities:''
Loan payable123,669145,458
Revolving line of credit229,980'
Unsecured notes payable1,246,335'
Total long-term liabilities1,599,984145,458
Total liabilities2,161,7101,267,175
Commitments and contingencies'  '  
Stockholders' equity:''
Preferred stock value89101
Common stock value843808
Additional paid-in capital9,752,6898,483,727
Accumulated deficit-9,130,633-6,813,758
Total stockholders' equity622,9881,670,878
Total liabilities and stockholders' equity$2,784,698 $2,938,053

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)Jun. 30, 2014Dec. 31, 2013
Preferred Stock, Par Value$0.00 $0.00
Preferred Stock, Shares Authorized4,500,0004,500,000
Preferred Stock, Issued887,3031,005,648
Common Stock, Par Value$0.00 $0.00
Common Stock, Shares Authorized20,000,00020,000,000
Common Stock, Issued8,430,6658,082,000
Common Stock, Outstanding8,283,7308,082,000
Preferred Series B''
Preferred Stock, Par Value$0.00 $0.00
Preferred Stock, Shares Authorized1,500,0001,500,000
Preferred Stock, Issued0177,000
Liquidation preference$0 $416,227
Preferred Series C''
Preferred Stock, Par Value$0.00 $0.00
Preferred Stock, Shares Authorized760,000760,000
Preferred Stock, Issued0101,000
Liquidation preference0224,668
Preferred Series D''
Preferred Stock, Par Value$0.00 $0.00
Preferred Stock, Shares Authorized1,500,0001,500,000
Preferred Stock, Issued887,303727,648
Liquidation preference$2,576,188 $2,403,691

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)3 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013
Income Statement''''
Equipment sales$77,000 $96,000 $84,445 $115,200
Service revenue30,975'43,875'
Other revenue4,8601,2804,8601,280
Total revenue112,83597,280133,180116,480
Costs of goods sold70,19261,52579,33273,650
Gross profit42,64335,75553,84842,830
Expenses:''''
Selling, general and administrative712,406665,6051,517,4121,402,171
Impairment of goodwill''390,659'
Research and development68,49563,360168,264134,986
Total expenses780,901728,9652,076,3351,537,157
Loss from operations-738,258-693,210-2,022,487-1,494,327
Other Income and Expense:''''
Interest income2393741,034
Interest expense-112,935-33,754-173,032-49,643
Total other income and expense-112,933-33,361-172,958-48,609
Loss before income taxes-851,191-726,571-2,195,445-1,542,936
Income taxes-25'-50'
Net loss-851,216-726,571-2,195,495-1,542,936
Preferred stock cumulative dividend61,13541,78759,15483,112
Net loss available to common stockholders($912,351)($768,358)($2,254,649)($1,626,048)
Net loss per common share basic and diluted($0.11)($0.34)($0.27)($0.79)
Weighted average shares outstanding basic and diluted8,397,4422,233,4148,331,5832,067,628

CONSOLIDATED_STATEMENT_OF_CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)6 Months Ended
Jun. 30, 2014Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:''
Net loss($2,195,495)($1,542,936)
Adjustments to reconcile net loss to net cash used in operating activities:''
Depreciation expense45,13326,256
Amortization of intangible asset178,570178,571
Amortization of discount on notes payable72,357'
Impairment of goodwill390,659'
Stock-based compensation and other non-cash expense163,72149,693
Changes in operating assets and liabilities''
(Increase) decrease in receivables-79,830-30,203
(Increase) decrease in prepaid and other current assets-15,9441,408
(Increase) decrease in inventory-61,733-149,623
Increase (decrease) in accounts payable6,194160,109
Increase (decrease) in accrued liabilities-199,458-60,182
Cash used in operating activities-1,695,826-1,366,907
CASH FLOWS FROM INVESTING ACTIVITIES:''
Purchases of property and equipment15,7727,332
Cash from acquisition of subsidiary3,355'
Cash used in investing activities-12,417-7,332
CASH FLOWS FROM FINANCING ACTIVITIES:''
Proceeds from issuance of unsecured notes payable1,570,000'
Proceeds from issuance of senior secured notes payable'990,087
Repayment of senior subordinated notes payable500,000'
Proceeds from issuance of preferred shares, net509,963'
Repayment of loan payable18,68513,519
Cash provided by (used in) financing activities1,561,278976,568
Net change in cash and cash equivalents-146,965-397,671
Cash and cash equivalents, beginning of period186,8641,027,475
Cash and cash equivalents, end of period$39,899 $629,804

Principal_Business_Activities

Principal Business Activities3 Months Ended
Jun. 30, 2014
Notes'
Principal Business Activities'
1.  PRINCIPAL BUSINESS ACTIVITIES:
Organization and Business - Heatwurx, Inc., a Delaware corporation (“Heatwurx,” or the “Company”), is an asphalt repair equipment and technology company.  Heatwurx was incorporated on March 29, 2011 as Heatwurxaq, Inc. and subsequently changed its name to Heatwurx, Inc. on April 15, 2011.  On January 1, 2014, Heatwurx acquired Dr. Pave, LLC a service company offering asphalt repair and restoration.  (Note 5)

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies3 Months Ended
Jun. 30, 2014
Notes'
Basis of Presentation and Summary of Significant Accounting Policies:'
2.  BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Basis of Presentation - These unaudited interim consolidated financial statements and related notes are presented in accordance with the accounting principles generally accepted in the United States (“U.S. GAAP”). Accordingly, they do not include all disclosures required in the annual financial statements by U.S. GAAP.  In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments considered necessary to present fairly in all material respects the financial position as of June 30, 2014. 
These financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2013, and have been prepared on a consistent basis with the accounting policies described in Note 2 - Summary of Significant Accounting Policies of the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.  Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014 or any future period.
The Company’s unaudited interim consolidated financial statements include Dr. Pave, LLC a wholly-owned subsidiary.  All intercompany investments, accounts and transactions have been eliminated.
The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.
The Company also faces certain risks and uncertainties which are present in many emerging companies regarding product development, future profitability, ability to obtain future capital, protection of patents and property rights, competition, rapid technological change, government regulations, recruiting and retaining key personnel, and third party manufacturing organizations.
To date we have relied exclusively on private placements with a small group of investors to finance our business and operations.  We have had little revenue since our inception.  For the six months ended June 30, 2014, the Company incurred a net loss of $2,195,495 and utilized approximately $1,695,826 in cash flows from operating activities.  The Company had cash on hand of $39,899 as of June 30, 2014.  Successful completion of the Company’s development program and its transition to profitable operations is dependent upon obtaining additional financing adequate to fulfill its development and commercialization activities, and achieve a level of revenues adequate to support the Company’s cost structure.  Many of the Company’s objectives to establish profitable business operations rely upon the occurrence of events outside its control; there is no assurance that the Company will be successful in accomplishing these objectives. We cannot assure that additional debt, equity or other funding will be available to us on acceptable terms, if at all.  If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate our operations, or seek to merge with or be acquired by another company.
Management anticipates that the Company will require additional funds to continue operations.  As of June 30, 2014, we had approximately $40,000 cash on hand.  Adjusting for $390,658 in one-time expense for impairment of goodwill from the acquisition of Dr. Pave, LLC in the first quarter 2014, our spending on operations is approximately $275,000 per month, of which only a very small amount is satisfied by revenues.  The amount of cash on hand is not adequate to meet our operating expenses over the next twelve months.  The Company raised $145,000 and $184,000 through unsecured notes in July and August 2014, respectively, in relation to a $3,000,000 private debt offering.
The issues described above raise substantial doubt about the Company’s ability to continue as a going concern. Although we have $1,951,000 remaining under the $3,000,000 debt offering, we cannot guarantee we will be able to raise the entire offering amounts, if any. We are solely reliant on raising additional capital in order to maintain our current operations.  To date we have been able to raise debt and equity financing through the assistance of a small number of our investors who have been substantial participants in our debt and equity offerings since our formation.  If these investors choose not to assist us with our capital raising initiatives in the future, we do not expect that we would be able to obtain any alternative forms of financing at this time and we would not be able to continue to satisfy our current or long term obligations.  Based upon our current monthly spending we anticipate the need to raise at least $2,000,000 to $3,000,000 to meet our cash flow requirements for the next twelve months.  If we successfully raise $2,000,000 to $3,000,000 in the private debt offering, we believe the proceeds we will receive and anticipated revenues from equipment sales and restoration services will be sufficient to fund our operations, including our expected capital expenditures, through the next twelve months.  Without these additional funds, we will be required to reduce operations, curtail any future growth opportunities, cease operations all together, or seek to merge with or be acquired by another company.
The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should the Company be unable to continue as a going concern.
Accounts Receivable and Bad Debt Expense - Management reviews individual accounts receivable balances that exceed 90 days from the invoice date. Based on an assessment of creditworthiness of the customer, the Company estimates the portion, if any, of the balance that will not be collected. All accounts deemed to be uncollectible are written off to operation expense. There was no allowance for uncollectible accounts as of June 30, 2014 and December 31, 2013, respectively.
Recent Accounting Pronouncements - The Financial Accounting Standards Board recently issued Accounting Standards Update (ASU) 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates the financial reporting distinction of being a development stage entity within U.S. generally accepted accounting principles. Accordingly, the ASU eliminates the incremental requirements for development stage entities to (a) present inception-to-date information in the statements of income, cash flows and shareholder’s equity, (b) label the financial statements as those of a development stage entity, (c) disclose a description of the development stage activities in which the entity is engaged and (d) disclose in the first year in which the development stage entity that in prior years it had been in the development stage. The amendments related to the elimination of inception-to-date information should be applied retrospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of these amendments is permitted for any annual reporting period or interim period for which the entity’s financials statements has not yet been issued.  The company has elected early application of these amendments with the quarterly report filed for June 30, 2014.
The Financial Accounting Standards Board recently issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), was issued in three parts: (a) "Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs—Contracts with Customers (Subtopic 340-40)," (b) "Conforming Amendments to Other Topics and Subtopics in the Codification and Status Tables," and (c) "Background Information and Basis for Conclusions."  The new presentation guidance is effective for interim and annual periods beginning after December 15, 2016.  We are considering the impact of the adoption of ASU 2014-09 on our results of operations, financial condition and cash flows.

Property_and_Equipment_Disclos

Property and Equipment Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Property and Equipment Disclosure'
3.  PROPERTY AND EQUIPMENT:
A summary of the cost of property and equipment, by component, and the related accumulated depreciation is as follows:
June 30,December 31,
20142013
(unaudited)
Office furniture and equipment$29,205$20,562
Demo and service equipment541,228426,336
  570,433446,898
Accumulated depreciation-126,765-77,123
  $443,668$369,775
Depreciation expense was $23,358 and $45,133 for the three and six months ended June 30, 2014 and $13,223 and $26,256 for the three and six months ended June 30, 2013.

Asset_Purchase_Agreement_Discl

Asset Purchase Agreement Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Asset Purchase Agreement Disclosure'
4.  ASSET PURCHASE AGREEMENT:
On April 15, 2011, the Company entered into an Asset Purchase Agreement with an individual who is a founder and a current stockholder. Pursuant to the agreement, the Company purchased the related business and activities of the design, manufacture and distribution of asphalt repair machinery under the Heatwurx brand. The total purchase price was $2,500,000. The purchase price was paid in a $1,500,000 cash payment and the issuance of a senior subordinated note to the seller in the amount of $1,000,000. (Note 6)
The business essentially consisted of the investment in research and development of the technology, the patents applied for as a result of the research and development activities and certain distribution relationships that were in process, but not finalized as of the acquisition date. Collectively, these investments constitute the in-process research and development we refer to as the “asphalt preservation and repair solution.” The Company capitalized $2,500,000 of in-process research and development related to this asphalt preservation and repair solution. As of October 1, 2012, in-process research and development is now classified as developed technology and amortized over its estimated useful life of seven years. The initial estimated fair value of the in-process research and development was determined using the income approach.  Under the income approach, the expected future cash flows from the asset are estimated and discounted to its net present value at an appropriate risk-adjusted rate of return.  The Company performed its annual impairment analysis in October of 2013.  The Company used the Relief-from-Royalty method.  The Company believes that is the most appropriate method for valuing the developed technology as it is a revenue generating technology.  As of June 30, 2014, our developed technology intangible asset had a value of $1,875,002, net of accumulated amortization of $624,998.  Amortization expense for the three and six months ended June 30, 2014 and 2013 was $89,285 and $178,570, respectively.
In conjunction with the Asset Purchase Agreement, the Company granted 200,000 performance stock options to a founder of the Company with an exercise price of $0.40 per share and a term of seven years. Following the effectiveness of the 7 for 1 stock split that was completed in October 2011, the 200,000 performance stock options were exchanged for 1,400,000 performance stock options with an exercise price of $0.057 per share.  As of June 30, 2014 there is no expectation that these performance stock options will vest.

Acquisition_Disclosure

Acquisition Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Acquisition Disclosure'
5.  ACQUISITION:
On January 7, 2014, the Company entered into an Agreement and Plan of Reorganization (the “Acquisition Agreement”) dated January 8, 2014 with Dr. Pave, LLC, a California limited liability company (“Dr. Pave”).  Dr. Pave was controlled by David Dworsky, the Chief Executive Officer of the Company.  The acquisition of Dr. Pave gives the Company the immediate ability to provide service work to municipalities and other end purchasers of Heatwurx equipment.  By performing the service work, management of the Company believes that it will assist the Company in generating purchase interest for Heatwurx equipment as well as possibly open other revenue opportunities such as franchising the service business.  The Company acquired all of the outstanding membership interests in Dr. Pave for 58,333 shares of common stock of the Company at a value of $3.00 per share for consideration in the amount of $175,000.  The consideration included the issuance of 41,668 shares to Dworsky Partners, LLC, an entity in which David Dworsky owned 80% of the ownership interest, and 3,333 shares to Reginald Greenslade, one of the Company’s directors.  As a result of the acquisition, which closed on January 8, 2014, Dr. Pave became a wholly owned subsidiary of the Company.  Dr. Pave is managed by David Dworsky and Justin Yorke, a shareholder of the Company.  The parties to the Acquisition Agreement established the effective date of the closing of the transaction for tax and accounting purposes as 8:00 a.m. on January 1, 2014.
The securities offered and sold in the above transactions have not been and will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
As of January 1, 2014, Dr. Pave had net liabilities of $215,659 assumed by the Company; in addition to the consideration of 58,333 shares of common stock valued at $175,000.  The total consideration paid in the acquisition of Dr. Pave resulted in goodwill in the amount of $390,659.  The Company determined that the goodwill was immediately impaired as of the acquisition date based on the lack of service revenue for the prior year.  An impairment of goodwill from the acquisition in the amount of $390,659, was recorded as an operating expense in the income statement for the six months ended June 30, 2014.

Notes_Payable_Disclosure

Notes Payable Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Notes Payable Disclosure'
6.  NOTES PAYABLE:
Unsecured Notes Payable - The Company issued senior unsecured notes payable totaling $90,000 on December 11, 2013.  The notes bear interest at a rate of 12% per annum.  Interest is payable monthly on the first day of each month.  The principal amount and all then-accrued and unpaid interest is payable on June 30, 2015.
On January 6, 2014, the Company commenced a non-public offering of notes and warrants of up to $1,000,000.  The promissory notes will bear interest at 12% per annum payable monthly, with principal and unpaid interest due and payable on January 6, 2016.  As additional consideration for a lender to enter into the Loan Agreement, the Company has agreed to issue to each lender one common stock purchase warrant for each $3.00 loaned to the Company.  The warrants expire three years following the date of issuance and may not be offered for sale, sold, transferred or assigned without the consent of the Company.  The three-year warrants will be exercisable immediately at $3.00 per share.
On February 28, 2014, the Company closed its $1,000,000 debt financing.  The total notes issued were in the aggregate principal amount of $850,000 and were issued with an aggregate of 283,329 warrants to the investors.  The warrants are detachable and exercisable immediately.  The Company allocated the fair value of the warrants in the amount of $248,129 as a discount on notes payable which will be amortized over the term of the notes to interest expense in the income statement. The Company recognized amortization of discount on notes payable in interest expense of $32,087 and $52,435 for the three and six months ended June 30, 2014, respectively.
On March 1, 2014, the Company commenced a similar non-public offering of notes and warrants up to $3,000,000 which is intended to remain open until December 31, 2014, unless terminated sooner at the option of the Company before all of the notes are sold.  The promissory notes will bear interest at 12% per annum payable monthly, with principal and unpaid interest due and payable on January 6, 2016.  Persons holding promissory notes issued by the Company in prior offerings may convert these notes into the notes and warrants being offered in this new offering.  Each lender in the offering will receive one warrant for each $3.00 loaned.  The three-year warrants will be exercisable immediately at $3.00 per share.  As of June 30, 2014, the Company issued notes in the aggregate principal amount of $720,000 and were issued with an aggregate of 240,000 warrants to the investors.  The warrants are detachable and exercisable immediately.  The Company allocated the fair value of the warrants in the amount of $147,894 as a discount on notes payable which will be amortized over the term of the notes to interest expense in the income statement.  The Company recognized amortization of discount on notes payable in interest expense of $19,184 and $19,922 for the three and six months ended June 30, 2014, respectively.
Revolving line of credit - The Company assumed a revolving line of credit entered into by Dr. Pave at its inception in July 2013 in the amount of $229,980.  The balance on the line of credit bears interest at a rate of 12% per annum.  Interest is payable monthly on the first day of each month.  The principal amount and all then-accrued and unpaid interest is payable on August 15, 2015.  Interest on the line of credit totaling $2,268 was outstanding at June 30, 2014.
Secured Notes Payable - The Company assumed secured notes payable issued by Dr. Pave on December 11, 2013 totaling $160,000. The notes bear interest at a rate of 12% per annum.  Interest is payable monthly on the first day of each month.  The principal amount and all then-accrued and unpaid interest is payable on June 30, 2015.
Interest on the secured notes payable totaling $1,578 was outstanding at June 30, 2014. 
Senior Subordinated Note Payable - The Company issued a senior subordinated note payable in the amount of $1,000,000 on April 15, 2011 to Richard Giles, a founder, stockholder and former director of the Company.  The note bears interest at a rate of 6% per annum and matured on April 15, 2014. The holder of the senior subordinated note agreed to subordinate to the lenders of the senior secured notes his security interest in our assets granted under the Subordinated Security Agreement dated April 15, 2011.  Mandatory principal payments of $500,000 were made in 2013 and the Company made the final required principal payments totaling $500,000 during the first half of 2014.
Loan Payable - In September 2012, the Company financed the purchase of equipment used for transport and demonstration of our equipment.  The note, in the original amount of $142,290, bears interest at a rate of 2.6% per annum and matures on September 4, 2017.  In August 2013, the Company financed the purchase of a truck to transport our equipment used in demonstrations.  The loan, in the amount of $83,507, bears interest at a rate of 6.1% per annum and matures on December 1, 2018. 
As of June 30, 2014, the loans are subject to mandatory principal payments as follows:
Year ending December 31,Payments
2014$22,500
2015523,981
20161,615,725
201737,361
201818,372
Total principal payments$2,217,939

Stockholders_Equity_Disclosure

Stockholders' Equity Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Stockholders' Equity Disclosure'
7.  STOCKHOLDERS’ EQUITY:
Common Stock - The Company has authorized 20,000,000 common shares with a $0.0001 par value. There were 8,430,665 issued and 8,283,730 outstanding at June 30, 2014 and 8,082,000 shares issued and outstanding at December 31, 2013, respectively.
Preferred Stock - The Company has authorized 4,500,000 shares of Preferred Stock with a $0.0001 par value.  As holders of any series of preferred stock convert into common shares the preferred shares are no longer outstanding and become available for reissuance.  As of June 30, 2014 and December 31, 2013, there were 887,303 and 1,005,648 preferred shares outstanding, respectively.
Series B Preferred Stock - As of June 30, 2014 there were no shares of Series B Preferred Stock outstanding.
On April 14, 2014 all remaining Series B preferred shares, 101,935, were mandatorily converted into common shares.   The conversion of Series B preferred shares to common shares resulted in a release of $40,529 in accumulated dividends during the quarter ended June 30, 2014.
Series C Preferred Stock - As of June 30, 2014 there were no shares of Series C Preferred Stock outstanding.
On April 14, 2014 all remaining Series C preferred shares, 45,000, were mandatorily converted into common shares.  Holders of Series C Preferred Stock accrued dividends at the rate per annum of $0.16 per share. At June 30, 2014, Series C Preferred Stock had dividends accumulated of $17,870.  The Company has dividends payable of $17,870 included in current liabilities as of June 30, 2014.
Series D Preferred Stock - As of June 30, 2014 there were 887,303 shares of Series D Preferred Stock outstanding.
In October 2013, the Company initiated a follow-on Series D Preferred stock offering to sell the remaining 772,352 units at $3.00 per unit for up to $2,317,056 gross proceeds. The offering includes an over-allotment of 1,000,000 units for an additional $3,000,000 in potential gross proceeds.  The offering term was extended and ended May 30, 2014.  The terms of the follow-on Series D preferred stock offering are the same as the original Series D preferred stock offering.
In January 2014, the Company issued 53,332 units sold at $3.00 per unit for gross proceeds of $159,996.  The Company paid share issuance costs in the amount of $6,000.  Each unit in this offering consists of one share of the Company’s Series D Preferred Stock and one-half warrant, with each whole warrant exercisable at $3.00 per share.  The Company issued warrants to purchase 26,666 shares of common stock outstanding. The warrants will be exercisable by the holders at any time on or after the issuance date of the warrants through and including one year from their respective issuance dates.
In May 2014, the Company issued 118,655 units sold at $3.00 per unit for gross proceeds of $355,966.  Each unit consisted of one share of the Company’s Series D Preferred Stock and one-half warrant, with each whole warrant exercisable at $3.00 per share.  The Company issued warrants to purchase 59,327 shares of common stock. The warrants will be exercisable by the holders at any time through and including one year from their respective issuance dates.
Holders of Series D Preferred Stock accrue dividends at the rate per annum of $0.24 per share, payable on a quarterly basis. As dividends are accrued and payable quarterly on the Series D Preferred Stock, the Company paid dividends of $45,665 and $89,683 during the three and six months ended June 30, 2014, respectively. As of June 30, 2014 the Company had dividends payable in accrued expenses of $49,237.
The holders of the Series D Preferred Stock have conversion rights equivalent to such number of fully paid and non-assessable shares of common stock as is determined by dividing the Series D original issue price of $3.00 by the then applicable conversion price. Each Series D Share will convert into one share of our common stock at any time at the option of the holder of the Series D Shares or will be converted at the option of the Company at any time the trading price of our common stock is at least $4.50 per share for ten consecutive trading days. The conversion ratio is subject to anti-dilution adjustments, including in the event that the Company issues equity securities at a price equivalent to or less than the conversion price in effect immediately prior to such issue. We have determined that there is a beneficial conversion feature (“BCF”).  The calculated value as of the commitment date of the BCF was $24,279, which represents the difference between the effective conversion price and the stated conversion price multiplied by the total number of shares which may be converted.  We have recorded this amount as a deemed dividend as of the date of issuance, as the Series D Preferred Stock is immediately convertible.  This amount was recorded as a charge against our accumulated deficit in our accompanying balance sheet.
The holders of Series D Preferred Stock have a liquidation preference over the holders of the Company’s common stock equivalent to the purchase price per share of the Series D Preferred Stock plus any accrued and unpaid dividends, whether or not declared, on the Series D Preferred Stock. A liquidation would be deemed to occur upon the happening of customary events, including transfer of all or substantially all of the Company’s common stock or assets or a merger, or consolidation. The Company believes that such liquidation events are within its control and therefore the Company has classified the Series D Preferred Stock in stockholders’ equity.
The holders of Series D Preferred Stock vote together as a single class with the holders of the Company’s common stock on all action to be taken by the Company’s stockholders. Each share of Series D Preferred Stock entitles the holder to the number of votes equal to the number of shares of common stock into which the shares of the Series D Preferred Stock are convertible as of the record date for determining stockholders entitled to vote on such matter.
Each unit includes one-half warrant.  Each full warrant grants the right to purchase a share of the Company’s common stock and, as of June 30, 2014, there were warrants to purchase 449,817 shares of common stock outstanding.  The warrants issued with the original Series D offering will be exercisable by the holders at any time on or after the issuance date of the warrants through and including October 1, 2014.  The warrants issued with the follow-on Series D offering will be exercisable by the holders at any time on or after the issuance date of the warrants through and including one year from their respective issuance dates.
In addition, the Company agreed to use its best efforts to register the shares underlying the warrants issued in the follow-on Series D preferred stock offering and the original Series D preferred stock offering.  The Company intends to file the registration statement not later than 90 days following the completion of the offering, May 30, 2014, and will use its best efforts to maintain the effectiveness of the registration statement for the investors in this and the prior offering through December 31, 2015.
Stock Options
Number of Weighted Weighted
OptionsAverage Average
Exercise Remaining
PriceLife
(Years)
Balance, December 31, 20121,022,000$2.00
Granted410,000$2.76
Exercised-$      -
Cancelled-112,000$2.00
Balance, December 31, 20131,320,000$2.23 3.44
Granted298,000$3.00
Exercised-$      -
Cancelled-206,500$2.27
Balance, June 30, 20141,411,500$2.39 3.35
Exercisable, December 31, 2013845,000$2.04
Exercisable, June 30, 2014825,500$2.14
On January 13, 2014, the Board of Directors approved the grant of 94,000 options to employees of the Company, in accordance with the terms of the 2011 Equity Incentive Plan, as amended. One-third of the options vest immediately, with the remaining vesting over a 2 year period.  The options have an exercise price of $3.00 per share, with an expiration date of five years from the grant date. 
On January 16, 2014, the Board of Directors approved the grant of 40,000 options to the Company’s Directors for their 2013 service, in accordance with the terms of the 2011 Equity Incentive Plan, as amended. The options vest immediately and have an exercise price of $3.00 per share, with an expiration date of five years from the grant date. 
On February 1, 2014, the Board of Directors approved the grant of 50,000 options to an employee of the Company, in accordance with the terms of the 2011 Equity Incentive Plan, as amended. The options vest ratably over a four year period.  The options have an exercise price of $3.00 per share, with an expiration date of five years from the grant date.
On April 4, 2014, the Board of Directors approved the grant of 4,000 options to employees of the Company, in accordance with the terms of the 2011 Equity Incentive Plan, as amended. One-third of the options vest immediately, with the remaining vesting over a 2 year period.  The options have an exercise price of $3.00 per share, with an expiration date of five years from the grant date.
On June 19, 2014, the Board of Directors approved the grant of 10,000 options to the new Secretary of the Board.  The options vest immediately.  The options have an exercise price of $3.00 per share, with an expiration date of five years from the grant date.
On June 19, 2014, the Board of Directors approved the grant of 100,000 options to an employee of the Company, in accordance with the terms of the 2011 Equity Incentive Plan, as amended. The options vest ratably over a three year period.  The options have an exercise price of $3.00 per share, with an expiration date of five years from the grant date.
The fair value of each stock option granted was estimated on the date of grant using the Black Scholes option pricing model with the following assumptions:
30-Jun-14
Risk-free interest rate range1.49% - 1.71%
Expected life5.0 years
Vesting Period0 - 4 Years
Expected volatility42%
Expected dividend-
Fair value range of options at grant date$0.671- $1.167
The Company recorded stock-based compensation expense of $34,313 and $163,721 during the three and six months ended June 30, 2014, respectively.  The Company recorded stock-based compensation expense of $30,371 and $49,693 during the three and six months ended June 30, 2013, respectively.
As of June 30, 2014 there was $449,286 of unrecognized compensation expense related to the issuance of the stock options.
Performance Stock Options
There were no performance stock options granted during the three and six months ended June 30, 2014.
Number of OptionsWeighted Average Exercise Price
Balance, December 31, 20121,440,000$0.11
Granted-$       -
Exercised-$       -
Cancelled-$       -
Balance, June 30, 2014 and December 31, 20131,440,000$0.11
Exercisable, June 30, 2014 and December 31, 201340,000$2.00
See Note 4 for further discussion of the performance options.
Warrants
The Company issued 85,993 warrants in connection with the follow-on Series D unit offering during the first half of 2014, discussed above. Each unit consisted of one share of Series D Preferred Stock and one-half warrant, with each whole warrant exercisable at $3.00 per share and grants the right to purchase a share of the Company’s common stock.
The Company issued 283,329 warrants in connection with the non-public offering of notes and warrants up to $1,000,000.  The warrants expire three years from the date of issuance and are exercisable immediately at $3.00 per share.
The Company issued 239,997 warrants in connection with the non-public offering of notes and warrants up to $3,000,000.  The warrants expire three years from the date of issuance and are exercisable immediately at $3.00 per share.
Number of Weighted Weighted
WarrantsAverage Average
Exercise Remaining
PriceLife
(Years)
Balance, December 31, 2013363,824$3.00
Granted609,319$3.00
Exercised-$      -
Cancelled-$      -
Balance, June 30, 2014973,143$3.00 2.53

Net_Loss_Per_Common_Share_Disc

Net Loss Per Common Share Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Net Loss Per Common Share Disclosure'
8.  NET LOSS PER COMMON SHARE:
The Company computes loss per share of common stock using the two-class method required for participating securities.  Our participating securities include all series of our convertible preferred stock.  Undistributed earnings allocated to these participating securities are added to net loss in determining net loss attributable to common stockholders.  Basic and Diluted loss per share are computed by dividing net loss attributable to common stockholder by the weighted-average number of shares of common stock outstanding. 
Outstanding options were not included in the computation of diluted loss per share because the options' exercise price was greater than the average market price of the common shares and, therefore, the effect would be anti-dilutive. 
For the three months endedFor the six months ended
June 30,June 30,
2014201320142013
Net Loss($851,216)($726,571)($2,195,495)($1,542,936)
Basic and diluted:
Preferred stock cumulative dividend - Series A--715--1,421
Preferred stock cumulative dividend - Series B (1)67027,868-62,22755,429
Preferred stock cumulative dividend - Series C29613,2042,20026,262
Preferred stock cumulative dividend - Series D60,169--119,181--
Income applicable to preferred stockholders61,13541,78759,15483,112
Net loss applicable to common stockholders($912,351)($768,358)($2,254,649)($1,626,048)
The calculation of the numerator and denominator for basic and diluted net loss per common share is as follows:
(1)   Upon conversion of the Series B preferred stock into common stock, the holders of the Series B preferred stock were no longer entitled to the dividends recorded in the adjustment to net loss applicable to common shareholders in prior periods.  As a result, current year reported dividends were adjusted downward to reflect this release of accumulated dividends.

Commitments_and_Contingencies_

Commitments and Contingencies Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Commitments and Contingencies Disclosure'
9.  COMMITMENTS AND CONTINGENCIES:
Lease Commitments - On July 18, 2012, the Company entered into a thirteen month lease for office space for our corporate headquarters located in Greenwood Village, Colorado.  Under the terms of the lease agreement, the Company leased approximately 2,244 square feet of general office space.  The lease term commenced on July 23, 2012 and ended June 30, 2014. 
The Company also has a lease of warehouse and office space for our equipment and operations located in Gardena, CA.  The lease term continues through July 2015.
Total rent expense for the three and six months ended June 30, 2014 was $19,305 and $38,404.  Rent expense for the three and six months ended June 30, 2013 was $8,819 and $17,639; respectively.
The Company’s remaining commitment under its current lease terms through July 2015 is approximately $65,000.
Purchase Commitments - As of June 30, 2014, the Company’s outsourced manufacturing company has begun fabrication of our equipment resulting in a commitment to purchase the finished equipment totaling approximately $50,000.

Related_Party_Transactions

Related Party Transactions3 Months Ended
Jun. 30, 2014
Notes'
Related Party Transactions'
10.  RELATED PARTY TRANSACTIONS:
During the three and six months ended June 30, 2014, the Company paid consulting fees of $32,400 and $69,800, respectively to Mr. Richard Giles, a founder, stockholder, and former director of the Company.  During the three and six months ended June 30, 2013 the Company paid consulting fees of $47,400 and $94,800, respectively to Richard Giles. The Company had a Senior Subordinated note payable with Mr. Richard Giles, on April 15, 2014, the Company made the final required principal payment of $250,000 on the Senior Subordinated note payable. 
During the quarter ended June 30, 2014 the Company issued 16,659 Series D Preferred shares to Reginald Greenslade, one of the Company’s directors.  The Company issued 16,666 Series D Preferred shares to Gus Blass III, one of the Company’s directors. The Company issued 1,500 Series D Preferred shares to David Dworsky, the Chief Executive Officer of the Company. 

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information Disclosure3 Months Ended
Jun. 30, 2014
Notes'
Supplemental Cash Flow Information Disclosure'
11.  SUPPLEMENTAL CASH FLOW INFORMATION:
Six Months Ended June 30,
20142013
Cash paid for interest$152,813$49,643
Cash paid for income taxes$--$100
Series C Dividend payable in current liabilities$17,870$47,591
Series D Dividend payable in current liabilities$49,237$--
Non-Cash investing and financing transactions
Repayment of senior secured notes payable$--$--
with issuance of Series D preferred shares
Financing the purchase of equipment under a$--$--
5 year loan agreement
Beneficial conversion feature on warrants$24,279$--
issued in conjunction with Series D preferred shares
Shares issued in acquisition of Dr. Pave$175,000$--

Subsequent_Events

Subsequent Events3 Months Ended
Jun. 30, 2014
Notes'
Subsequent Events'
12.  SUBSEQUENT EVENTS:
Debt Offering
In July 2014 and August 2014, the Company received $145,000 and $184,000, respectively; under the $3,000,000 debt offering and issued warrants to purchase 109,666 shares of our common stock.
Termination of Consulting Agreement
Effective July 15, 2014, the Company terminated the Consulting Agreement with Richard Giles.
Establishment of Dr. Pave Worldwide LLC & National Franchising Program
Effective July 22, 2014, the Company established a new entity named Dr. Pave Worldwide LLC to house the recently announced [on Form 8-K filed August 7, 2014] franchise program providing franchisees with the exclusive Heatwurx equipment and processing.  The franchising program is on track with submission for regulatory approval.  Franchise sales are expected to be formally launched nationally beginning early third quarter 2014.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies: Basis of Presentation (Policies)3 Months Ended
Jun. 30, 2014
Policies'
Basis of Presentation'
Basis of Presentation - These unaudited interim consolidated financial statements and related notes are presented in accordance with the accounting principles generally accepted in the United States (“U.S. GAAP”). Accordingly, they do not include all disclosures required in the annual financial statements by U.S. GAAP.  In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments considered necessary to present fairly in all material respects the financial position as of June 30, 2014. 
These financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2013, and have been prepared on a consistent basis with the accounting policies described in Note 2 - Summary of Significant Accounting Policies of the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.  Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014 or any future period.
The Company’s unaudited interim consolidated financial statements include Dr. Pave, LLC a wholly-owned subsidiary.  All intercompany investments, accounts and transactions have been eliminated.
The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.
The Company also faces certain risks and uncertainties which are present in many emerging companies regarding product development, future profitability, ability to obtain future capital, protection of patents and property rights, competition, rapid technological change, government regulations, recruiting and retaining key personnel, and third party manufacturing organizations.
To date we have relied exclusively on private placements with a small group of investors to finance our business and operations.  We have had little revenue since our inception.  For the six months ended June 30, 2014, the Company incurred a net loss of $2,195,495 and utilized approximately $1,695,826 in cash flows from operating activities.  The Company had cash on hand of $39,899 as of June 30, 2014.  Successful completion of the Company’s development program and its transition to profitable operations is dependent upon obtaining additional financing adequate to fulfill its development and commercialization activities, and achieve a level of revenues adequate to support the Company’s cost structure.  Many of the Company’s objectives to establish profitable business operations rely upon the occurrence of events outside its control; there is no assurance that the Company will be successful in accomplishing these objectives. We cannot assure that additional debt, equity or other funding will be available to us on acceptable terms, if at all.  If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate our operations, or seek to merge with or be acquired by another company.
Management anticipates that the Company will require additional funds to continue operations.  As of June 30, 2014, we had approximately $40,000 cash on hand.  Adjusting for $390,658 in one-time expense for impairment of goodwill from the acquisition of Dr. Pave, LLC in the first quarter 2014, our spending on operations is approximately $275,000 per month, of which only a very small amount is satisfied by revenues.  The amount of cash on hand is not adequate to meet our operating expenses over the next twelve months.  The Company raised $145,000 and $184,000 through unsecured notes in July and August 2014, respectively, in relation to a $3,000,000 private debt offering.
The issues described above raise substantial doubt about the Company’s ability to continue as a going concern. Although we have $1,951,000 remaining under the $3,000,000 debt offering, we cannot guarantee we will be able to raise the entire offering amounts, if any. We are solely reliant on raising additional capital in order to maintain our current operations.  To date we have been able to raise debt and equity financing through the assistance of a small number of our investors who have been substantial participants in our debt and equity offerings since our formation.  If these investors choose not to assist us with our capital raising initiatives in the future, we do not expect that we would be able to obtain any alternative forms of financing at this time and we would not be able to continue to satisfy our current or long term obligations.  Based upon our current monthly spending we anticipate the need to raise at least $2,000,000 to $3,000,000 to meet our cash flow requirements for the next twelve months.  If we successfully raise $2,000,000 to $3,000,000 in the private debt offering, we believe the proceeds we will receive and anticipated revenues from equipment sales and restoration services will be sufficient to fund our operations, including our expected capital expenditures, through the next twelve months.  Without these additional funds, we will be required to reduce operations, curtail any future growth opportunities, cease operations all together, or seek to merge with or be acquired by another company.
The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should the Company be unable to continue as a going concern.

Basis_of_Presentation_and_Summ2

Basis of Presentation and Summary of Significant Accounting Policies: Accounts Receivable and Bad Debt Expense, Policy (Policies)3 Months Ended
Jun. 30, 2014
Policies'
Accounts Receivable and Bad Debt Expense, Policy'
Accounts Receivable and Bad Debt Expense - Management reviews individual accounts receivable balances that exceed 90 days from the invoice date. Based on an assessment of creditworthiness of the customer, the Company estimates the portion, if any, of the balance that will not be collected. All accounts deemed to be uncollectible are written off to operation expense. There was no allowance for uncollectible accounts as of June 30, 2014 and December 31, 2013, respectively.

Basis_of_Presentation_and_Summ3

Basis of Presentation and Summary of Significant Accounting Policies: Recent Accounting Pronouncements, Policy (Policies)3 Months Ended
Jun. 30, 2014
Policies'
Recent Accounting Pronouncements, Policy'
Recent Accounting Pronouncements - The Financial Accounting Standards Board recently issued Accounting Standards Update (ASU) 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates the financial reporting distinction of being a development stage entity within U.S. generally accepted accounting principles. Accordingly, the ASU eliminates the incremental requirements for development stage entities to (a) present inception-to-date information in the statements of income, cash flows and shareholder’s equity, (b) label the financial statements as those of a development stage entity, (c) disclose a description of the development stage activities in which the entity is engaged and (d) disclose in the first year in which the development stage entity that in prior years it had been in the development stage. The amendments related to the elimination of inception-to-date information should be applied retrospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of these amendments is permitted for any annual reporting period or interim period for which the entity’s financials statements has not yet been issued.  The company has elected early application of these amendments with the quarterly report filed for June 30, 2014.
The Financial Accounting Standards Board recently issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), was issued in three parts: (a) "Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs—Contracts with Customers (Subtopic 340-40)," (b) "Conforming Amendments to Other Topics and Subtopics in the Codification and Status Tables," and (c) "Background Information and Basis for Conclusions."  The new presentation guidance is effective for interim and annual periods beginning after December 15, 2016.  We are considering the impact of the adoption of ASU 2014-09 on our results of operations, financial condition and cash flows.

Property_and_Equipment_Disclos1

Property and Equipment Disclosure: Summary of the cost of property and equipment (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Summary of the cost of property and equipment'
June 30,December 31,
20142013
(unaudited)
Office furniture and equipment$29,205$20,562
Demo and service equipment541,228426,336
  570,433446,898
Accumulated depreciation-126,765-77,123
  $443,668$369,775

Notes_Payable_Disclosure_Sched

Notes Payable Disclosure: Schedule of Loan Payable (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Loan Payable'
Year ending December 31,Payments
2014$22,500
2015523,981
20161,615,725
201737,361
201818,372
Total principal payments$2,217,939

Stockholders_Equity_Disclosure1

Stockholders' Equity Disclosure: Schedule of Stock Option Activity (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Stock Option Activity'
Number of Weighted Weighted
OptionsAverage Average
Exercise Remaining
PriceLife
(Years)
Balance, December 31, 20121,022,000$2.00
Granted410,000$2.76
Exercised-$      -
Cancelled-112,000$2.00
Balance, December 31, 20131,320,000$2.23 3.44
Granted298,000$3.00
Exercised-$      -
Cancelled-206,500$2.27
Balance, June 30, 20141,411,500$2.39 3.35
Exercisable, December 31, 2013845,000$2.04
Exercisable, June 30, 2014825,500$2.14

Stockholders_Equity_Disclosure2

Stockholders' Equity Disclosure: Schedule of Stock Option Valuation Assumptions (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Stock Option Valuation Assumptions'
30-Jun-14
Risk-free interest rate range1.49% - 1.71%
Expected life5.0 years
Vesting Period0 - 4 Years
Expected volatility42%
Expected dividend-
Fair value range of options at grant date$0.671- $1.167

Stockholders_Equity_Disclosure3

Stockholders' Equity Disclosure: Schedule of Performance Stock Options (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Performance Stock Options'
Number of OptionsWeighted Average Exercise Price
Balance, December 31, 20121,440,000$0.11
Granted-$       -
Exercised-$       -
Cancelled-$       -
Balance, June 30, 2014 and December 31, 20131,440,000$0.11
Exercisable, June 30, 2014 and December 31, 201340,000$2.00

Stockholders_Equity_Disclosure4

Stockholders' Equity Disclosure: Schedule of Stockholders' Equity Note, Warrants (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Stockholders' Equity Note, Warrants'
Number of Weighted Weighted
WarrantsAverage Average
Exercise Remaining
PriceLife
(Years)
Balance, December 31, 2013363,824$3.00
Granted609,319$3.00
Exercised-$      -
Cancelled-$      -
Balance, June 30, 2014973,143$3.00 2.53

Net_Loss_Per_Common_Share_Disc1

Net Loss Per Common Share Disclosure: Schedule of Earnings Per Share (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Earnings Per Share'
For the three months endedFor the six months ended
June 30,June 30,
2014201320142013
Net Loss($851,216)($726,571)($2,195,495)($1,542,936)
Basic and diluted:
Preferred stock cumulative dividend - Series A--715--1,421
Preferred stock cumulative dividend - Series B (1)67027,868-62,22755,429
Preferred stock cumulative dividend - Series C29613,2042,20026,262
Preferred stock cumulative dividend - Series D60,169--119,181--
Income applicable to preferred stockholders61,13541,78759,15483,112
Net loss applicable to common stockholders($912,351)($768,358)($2,254,649)($1,626,048)

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information Disclosure: Schedule of Cash Flow, Supplemental Disclosures (Tables)3 Months Ended
Jun. 30, 2014
Tables/Schedules'
Schedule of Cash Flow, Supplemental Disclosures'
Six Months Ended June 30,
20142013
Cash paid for interest$152,813$49,643
Cash paid for income taxes$--$100
Series C Dividend payable in current liabilities$17,870$47,591
Series D Dividend payable in current liabilities$49,237$--
Non-Cash investing and financing transactions
Repayment of senior secured notes payable$--$--
with issuance of Series D preferred shares
Financing the purchase of equipment under a$--$--
5 year loan agreement
Beneficial conversion feature on warrants$24,279$--
issued in conjunction with Series D preferred shares
Shares issued in acquisition of Dr. Pave$175,000$--

Basis_of_Presentation_and_Summ4

Basis of Presentation and Summary of Significant Accounting Policies: Basis of Presentation (Details) (USD $)3 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013
Details''''
Net loss during period$851,216 $726,571 $2,195,495 $1,542,936
Cash flows utilized in operating activities''1,695,826'
Cash on hand$39,899 '$39,899 '

Property_and_Equipment_Disclos2

Property and Equipment Disclosure: Summary of the cost of property and equipment (Details) (USD $)Jun. 30, 2014Dec. 31, 2013
Property, Plant and Equipment, Gross$570,433 $446,898
Accumulated depreciation-126,765-77,123
Equipment, net of depreciation443,668369,775
Computer Equipment''
Property, Plant and Equipment, Gross29,20520,562
Demo and service equipment''
Property, Plant and Equipment, Gross$541,228 $426,336

Property_and_Equipment_Disclos3

Property and Equipment Disclosure (Details) (USD $)3 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013
Details''''
Depreciation expense$23,358 $13,223 $45,133 $26,256

Asset_Purchase_Agreement_Discl1

Asset Purchase Agreement Disclosure (Details) (Asset Purchase Agreement, USD $)3 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2014Apr. 15, 2011
Asset Purchase Agreement'''
Total purchase price''$2,500,000
Cash payment''1,500,000
Issuance of senior subordinated note (value)''1,000,000
Developed technology intangible asset (value)1,875,0021,875,002'
Developed technology intangible asset (accumulated amortizaton)624,998624,998'
Developed technology intangible asset (amortization expense)$89,285 $178,570 '
Performance stock options granted''1,400,000
Performance stock options, exercise price''$0.06

Acquisition_Disclosure_Details

Acquisition Disclosure (Details) (USD $)6 Months Ended
Jun. 30, 2014Jan. 02, 2014
Impairment of goodwill, operating expense$390,659 '
Agreement and Plan of Reorganization''
Common stock issued for acquisition58,333'
Consideration for common stock issued for acquisition175,000'
Net liabilities assumed in acquisition'215,659
Total consideration in acquisition resulting in goodwill'390,659
Impairment of goodwill, operating expense$390,659 '

Notes_Payable_Disclosure_Detai

Notes Payable Disclosure (Details) (USD $)Jun. 30, 2014Aug. 30, 2013Sep. 30, 2012Dec. 11, 2013Jun. 30, 2014Jun. 30, 2014Feb. 28, 2014Jan. 06, 2014Jun. 30, 2014Jun. 30, 2014Mar. 01, 2014Jun. 30, 2014Dec. 31, 2013Jun. 30, 2014Dec. 11, 2013Apr. 15, 2011
Loan Payable DueLoan Payable DueSenior unsecured Notes PayableNotes and warrantsNotes and warrantsNotes and warrantsNotes and warrantsNotes and warrants(2)Notes and warrants(2)Notes and warrants(2)Revolving line of creditSecured Notes PayableSecured Notes PayableSecured Notes PayableSenior Subordinated Note Payable
Total amount of notes outstanding''$142,290 $90,000 ''$850,000 '$720,000 $720,000 '''''$1,000,000
Note interest rate''2.60%12.00%'''12.00%''12.00%'''12.00%'
Offering amount of notes and warrants'''''''1,000,000''3,000,000'''''
Amortization of discount on notes payable''''32,08752,435''19,18419,922''''''
Discount on notes payable''''''''147,894147,894''''''
Lin of credit229,980''''''''''229,980''''
Interest payable'''''''''''2,268'1,578''
Notes payable assumed''''''''''''160,000'''
Loan (financed purchase of truck)'$83,507 ''''''''''''''

Notes_Payable_Disclosure_Sched1

Notes Payable Disclosure: Schedule of Loan Payable (Details) (Loan Payable Due, USD $)Jun. 30, 2014
Loan Payable Due'
Mandatory principal loan payments (2014)$22,500
Mandatory principal loan payments (2015)523,981
Mandatory principal loan payments (2016)1,615,725
Mandatory principal loan payments (2017)37,361
Mandatory principal loan payments (2018)18,372
Total principal payments$2,217,939

Stockholders_Equity_Disclosure5

Stockholders' Equity Disclosure (Details) (USD $)3 Months Ended6 Months Ended12 Months Ended6 Months Ended1 Months Ended3 Months Ended6 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013Dec. 31, 2013Jun. 30, 2014Jun. 30, 201431-May-14Jan. 31, 2014Jun. 30, 2014Jun. 30, 2014Oct. 31, 2013Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014Jun. 30, 2014
Series B Preferred StockSeries C Preferred StockSeries D Preferred StockSeries D Preferred StockSeries D Preferred StockSeries D Preferred StockSeries D Preferred Stock2011 Equity Incentive Plan, January 13, 20142011 Equity Incentive Plan, January 16, 20142011 Equity Incentive Plan, February 1, 20142011 Equity Incentive Plan, April 4, 20142011 Equity Incentive Plan, June 19, 20142011 Equity Incentive Plan, June 19, 2014 (2)Series D Unit offeringNon-public offering of notes and warrantsNon-public offering of notes and warrants(2)
Common stock authorized20,000,000'20,000,000'20,000,000''''''''''''''''
Common shares issued8,430,665'8,430,665'8,082,000''''''''''''''''
Common stock outstanding8,283,730'8,283,730'8,082,000''''''''''''''''
Preferred stock authorized4,500,000'4,500,000'4,500,000''''''''''''''''
Preferred stock outstanding887,303'887,303'1,005,648''''''''''''''''
Preferred shares converted to common shares'''''101,93545,000''''''''''''''
Accumulated dividends released'''''$40,529 '''''''''''''''
Annual dividend rate''''''$0.16 '''$0.24 ''''''''''
Dividends accumulated''''''17,870''''''''''''''
Dividends payable''''''17,870''49,23749,237''''''''''
Shares outstanding'''''''''887,303887,303''''''''''
Units offered (Common Stock and Warrants)'''''''''''772,352'''''''''
Units offered (Common Stock and Warrants), price per unit'''''''''''$3 '''''''''
Units offered (Common Stock and Warrants), potential proceeds'''''''''''2,317,056'''''''''
Units offered (Common Stock and Warrants), additional over-allotment'''''''''''1,000,000'''''''''
Units offered (Common Stock and Warrants), potential proceeds for additional over-allotment'''''''''''3,000,000'''''''''
Units sold during offering'''''''118,65553,332''''''''''''
Gross proceeds from units sold in offering'''''''355,966159,996''''''''''''
Issuance costs''''''''6,000''''''''''''
Dividends paid'''''''''45,66589,683''''''''''
Original issue price per share'''''''''$3 $3 ''''''''''
Beneficial conversion feature (BCF)''''''''''24,279''''''''''
Number of options granted''298,000'410,000'''''''94,00040,00050,0004,00010,000100,000'''
Stock-based compensation expense34,31330,371163,72149,693'''''''''''''''''
Unrecognized compensation expense$449,286 '$449,286 ''''''''''''''''''
Number of warrants issued''''''''''''''''''85,993283,329239,997

Stockholders_Equity_Disclosure6

Stockholders' Equity Disclosure: Schedule of Stock Option Activity (Details) (USD $)6 Months Ended12 Months Ended
Jun. 30, 2014Dec. 31, 2013Dec. 31, 2012
Details'''
Number of options outstanding1,411,5001,320,0001,022,000
Weighted average exercise price, options outstanding$2.39 $2.23 $2
Number of options granted298,000410,000'
Weighted average exercise price, options granted$3 $2.76 '
Number of options cancelled206,500112,000'
Weighted average exercise price, options cancelled$2.27 $2 '
Weighted average remaining life (in years), options outstanding3.353.44'
Number of options exercisable825,500845,000'
Weighted average exercise price, options exercisable$2.14 $2.04 '

Stockholders_Equity_Disclosure7

Stockholders' Equity Disclosure: Schedule of Performance Stock Options (Details) (USD $)Jun. 30, 2014Dec. 31, 2012
Details''
Performance Stock options outstanding1,440,0001,440,000
Weighted average exercise price, performance stock options outstanding$0.11 $0.11
Performance Stock options exercisable40,000'
Weighted average exercise price, performance stock options exercisable$2 '

Stockholders_Equity_Disclosure8

Stockholders' Equity Disclosure: Schedule of Stockholders' Equity Note, Warrants (Details) (USD $)6 Months Ended
Jun. 30, 2014Dec. 31, 2013
Details''
Warrants outstanding973,143363,824
Weighted average exercise price, warrants$3 $3
Warrants granted609,319'

Net_Loss_Per_Common_Share_Disc2

Net Loss Per Common Share Disclosure: Schedule of Earnings Per Share (Details) (USD $)3 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013
Net income (loss)($851,216)($726,571)($2,195,495)($1,542,936)
Net income (loss) available to preferred stockholders61,13541,78759,15483,112
Net income (loss) applicable to common stockholders-912,351-768,358-2,254,649-1,626,048
Series A Dividend''''
Cumulative dividend'715'1,421
Series B Dividend''''
Cumulative dividend67027,868-62,22755,429
Series C Dividend''''
Cumulative dividend29613,2042,20026,262
Series D Dividend''''
Cumulative dividend$60,169 '$119,181 '

Commitments_and_Contingencies_1

Commitments and Contingencies Disclosure (Details) (USD $)3 Months Ended6 Months Ended23 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014
Details'''''
Lease commitment, terms'''''Company leased approximately 2,244 square feet of general office space
Total rent expense$19,305 $8,819 $38,404 $17,639 '
Commitment to purchase equipment$50,000 '$50,000 '$50,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)3 Months Ended6 Months Ended
Jun. 30, 2014Jun. 30, 2013Jun. 30, 2014Jun. 30, 2013
Richard Giles''''
Related party consulting fees$32,400 $47,400 $69,800 $94,800
Repayment of Senior Subordinated note payable''$250,000 '
Greenslade - Series D Preferred Shares''''
Stock issued to related parties16,659'''
Blass - Series D Preferred Shares''''
Stock issued to related parties16,666'''
Dworsky - Series D Preferred Shares''''
Stock issued to related parties1,500'''

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information Disclosure: Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)6 Months Ended
Jun. 30, 2014Jun. 30, 2013
Details''
Cash paid for interest$152,813 $49,643
Cash paid for income taxes'100
Series C Dividend payable in accounts payable17,87047,591
Series D Dividend payable in accrued expenses49,237'
Beneficial conversion feature on warrants issued in conjunction with Series D preferred shares24,279'
Shares issued in acquisition of Dr. Pave$175,000 '

Subsequent_Events_Details

Subsequent Events (Details) (Debt offering, USD $)0 Months Ended1 Months Ended
Aug. 15, 2014Jul. 31, 2014Aug. 15, 2014
Debt offering'''
Proceeds from debt offering$184,000 $145,000 '
Warrants issued with debt offering''109,666